2026-01-22 - Analysis Report
**Section 1: Company Overview**
Amgen is a biotechnology company that discovers, develops, manufactures, and delivers innovative therapies to patients suffering from severe and often life-threatening diseases.

**Section 2: Return Rate Comparison**
| Stock | Cumulative Return |
| --- | --- |
| AMGN (Review) | 77.83% |
| VOO (Comparison) | 91.55% |
Divergence: -13.72% (current position in the minimum-maximum fluctuation range is 32.90%)
The comparison stock (VOO) has a higher cumulative return rate than the review stock (AMGN), indicating a divergence of 13.72%.

**Section 3: Alpha and Beta Analysis**
| Period | CAGR | MDD | Alpha | Beta | Market Cap |
| --- | --- | --- | --- | --- | --- |
| 2016-2018 | 14.0% | 14.6% | 10.0% | 1.1 | 104.8B |
| 2017-2019 | 41.0% | 12.4% | 23.0% | 0.9 | 129.8B |
| 2018-2020 | 8.0% | 17.7% | -13.0% | 0.8 | 123.8B |
| 2019-2021 | 15.0% | 17.7% | -28.0% | 0.8 | 121.1B |
| 2020-2022 | 15.0% | 15.5% | 17.0% | 0.6 | 141.4B |
| 2021-2023 | 19.0% | 15.3% | 19.0% | 0.4 | 155.1B |
| 2022-2024 | 12.0% | 21.0% | -8.0% | 0.4 | 140.3B |
| 2023-2025 | 38.0% | 21.0% | -24.0% | 0.5 | 176.2B |

**Section 4: Recent Stock Price Fluctuations**
|  | Value |
| --- | --- |
| Close | $343.60 |
| Last-market | $343.60 ($3.81) |
| 5-day SMA | $332.80 |
| 20-day SMA | $330.28 |
| 60-day SMA | $325.94 |

**Section 5: RSI, PPO Index Indicators, and Delta_Previous_Relative_Divergence**
| Indicator | Value |
| --- | --- |
| MRI | 0.80 |
| RSI | 61.26 |
| PPO | 0.27 |
| Risk Level | Medium |
| Hybrid Signal | Buy |
| Recent relative divergence change | 4.00 (+) |
| 7-day Rank change | 26 (+) |
| 7-day Dynamic Expected Return change | 0.10 (+) |
| Expected Return (%) | -2.00% |

**Section 6: Recent News & Significant Events**
Please refer to the following news articles:

* AMGEN INC (NASDAQ:AMGN) Shows High Technical and Setup Ratings for Potential Breakout - Chartmill (news.google.com)
* Arkadios Wealth Advisors Increases Stock Holdings in Amgen Inc. $AMGN - MarketBeat (news.google.com)
* Amgen (NASDAQ:AMGN) Has Announced That It Will Be Increasing Its Dividend To $2.52 - Yahoo Finance (news.google.com)
* Amgen's (NASDAQ:AMGN) Shareholders Will Receive A Bigger Dividend Than Last Year - simplywall.st (news.google.com)
* Amgen (AMGN) Expands Obesity Strategy With Ro Collaboration on GLP-1 Therapies - Finviz (news.google.com)
* Notable Wednesday Option Activity: CRUS, AMGN, HUM - Nasdaq (news.google.com)

**Section 7: Analyst Opinions**
Analyst Consensus:
- Key: Buy
- Mean (1=StrongBuy~5=Sell): 2.41 (~Buy)
- Opinions: 27
- Target Price (avg/high/low): 331.59 / 425.00 / 180.00

**Section 8: Recent Earnings Analysis**
| Date | EPS | Revenue |
| --- | --- | --- |
| 2025-11-05 | 5.98 | $9.56B |
| 2025-08-06 | 2.66 | $9.18B |
| 2025-05-02 | 3.22 | $8.15B |
| 2024-10-31 | 5.27 | $8.50B |
| 2025-11-05 | 5.27 | $8.50B |

**Section 9: Financial Information**
**Revenue and Profitability**
| Quarter | Revenue | Profit Margin |
| --- | --- | --- |
| 2025-09-30 | $9.56B | 67.75% |
| 2025-06-30 | $9.18B | 67.20% |
| 2025-03-31 | $8.15B | 63.58% |
| 2024-12-31 | $9.09B | 65.75% |
| 2024-09-30 | $8.50B | 61.07% |

**Capital and Profitability**
| Quarter | Equity | ROE |
| --- | --- | --- |
| 2025-09-30 | $9.62B | 33.43% |
| 2025-06-30 | $7.43B | 19.28% |
| 2025-03-31 | $6.21B | 27.87% |
| 2024-12-31 | $5.88B | 10.67% |
| 2024-09-30 | $7.53B | 37.60% |

**Section 10: Comprehensive Analysis**
Summary of previous items:

* The review stock (AMGN) has a lower cumulative return rate than the comparison stock (VOO), indicating a divergence of 13.72%.
* The alpha and beta values for AMGN vary across different periods, with some periods indicating positive alpha and others indicating negative alpha.
* The recent stock price fluctuations show that the 60-day SMA is the lowest of the three moving averages, indicating a potential buy opportunity.
* The RSI, PPO, and MRI values indicate a medium risk level and a buy signal.
* Recent news articles suggest that AMGN has announced an increase in its dividend to $2.52, and has expanded its obesity strategy with a Ro collaboration on GLP-1 therapies.
* Analyst opinions indicate a buy consensus with a mean rating of 2.41 and a target price range of $331.59 to $425.00.
* The recent earnings analysis shows that AMGN has reported strong EPS and revenue growth in recent quarters.
* The financial information shows that AMGN has reported strong revenue and profit margin growth in recent quarters, with a profit margin range of 61.07% to 67.75% and an ROE range of 10.67% to 37.60%.

**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.